Co-Founder, Chief Executive Officer
David is responsible for the scientific development and implementation of Gatehouse Bio’s technology platform.
Prior to Gatehouse Bio, David was the head of radiogenomics at MiraDx, where he led the development of commercial diagnostics for radiation and immunotherapy response. As a scientist, David established multiple PK/PD and biomarker assays to support Biogen’s antisense oligo therapeutic pipeline. Over the last 20 years, David has contributed to the small RNA field where he created “gold standard” R&D tools, including the first anti-DICER mAbs and a reporter assay platform to measure small RNA function that has been used in >8,000 publications.
David earned his PhD in molecular biology from the University of Connecticut and completed a postgraduate fellowship in radiation oncology and molecular genetics at the Yale University School of Medicine.
Co-Founder, Chief Business Officer
Neal is responsible for establishing the business strategy and commercial framework for the company.
Prior to Gatehouse Bio, Neal has held multiple executive leadership roles in Fortune 100 companies, managing execution and sales for organizations focused on data-driven systems and platforms. As a serial intrapreneur, Neal has started new businesses within large organizations, including Motorola, VMware, and Dell, and has led the technical diligence for many mergers and acquisitions. Neal’s experience in building large scale ecosystems and complex commercial collaborations has led to creative partnerships that continue to drive growth within these companies.
Neal earned an MBA from the Wharton School of Business and a BS in computer and electrical engineering from Rutgers University. He is currently studying precision medicine at the Harvard Medical School. Neal holds 10 patents covering software architecture and complex data system design.
Chief Technology Officer
Nathan is responsible for architecting Gatehouse Bio’s database and software applications for small RNA featurization and analysis. He brings 20 years of experience in software engineering, with a strong focus on efficient and reliable signal extraction from large, noisy datasets, including computer vision, web analytics, tracking objects through multisource data fusion, and natural language search.
Prior to Gatehouse Bio, Nathan was vice president of technology at Textaurant,serving as the lead developer and engineering manager producing a data management platform. After less than 5 years from development-to-sales, the company was acquired. Most recently, Nathan improved the reliability and efficiency of TripAdvisor’s search tools, reducing run times by a factor of 10,000, memory requirements by a factor of 10, and improving search accuracy.
Nathan holds a BS in computer science from Worcester Polytechnic Institute.
Chief Operating Officer
Prior to joining Gatehouse Bio, Alan was the Director of Technology at Gee Partners and led projects for product testing, development, feasibility and commercialization in the high-tech space. Additionally, he supported strategic business initiatives, playing a key role in the acquisition and restructuring of RadioShack, which lead to the subsequent formation of General Wireless Operations dba RadioShack.
Earlier in his career, Alan served as the senior product development architect at Dell and was the director of 3GSM global portfolio management, the director of product operations for Europe, Middle East, and Africa, the director of engineering for CDMA performance category mobile phone development, and director of CDMA system and field testing. Prior to that, he was the lead engineering manager at Bell Laboratories for over 20 years, where he worked on breakthrough innovations and technologies such as high-speed cable, satellite transmission systems, wireless infrastructure, fiber-to-the-home, loop plant electronics, and wired products.
Alan holds a PhD in applied mechanics and mathematics, an MS in applied mechanics, and a BS in aerospace engineering from the NYU Polytechnic School of Engineering. He also holds a black belt in Six Sigma process management.
Kevin is responsible for overseeing and directing the lab functions at Gatehouse Bio. Kevin brings over 30 years of experience in molecular biology that covers basic research, transcriptomics, genomics, technology development, and clinical development.
Prior to Gatehouse Bio, Kevin was a research scientist at QIAGEN, where he developed products and technology for their Next-Generation Sequencing product line. Prior to that, Kevin was a research scientist at Vertex Pharmaceuticals, where he developed translational biomarker assays utilizing high-throughput transcriptomic platforms.
Kevin holds an MS in biochemistry/molecular biology from Boston University Medical School and a BA in biology from Saint Anselm College.
Sean manages early-stage commercial opportunities for Gatehouse Bio and supports senior management in forming collaborations with industry and academic partners. Sean also leads competitive intelligence and due diligence while working with senior management to execute business strategy.
Prior to Gatehouse Bio, Sean worked as a business development analyst at Neurocentrx Pharma, a specialty pharmaceutical company focused on neurology, and as a business development intern at Vasorum, a cardiovascular medical device company.
Sean holds an MSc in biotechnology and business from the UCD Michael Smurfit Graduate School of Business and a BSc in biochemistry and microbiology from the National University of Ireland, Galway. He is currently studying precision medicine at the Harvard Medical School.
Matt works on sRNA-signature identification and discovery for Gatehouse Bio’s pipeline programs. He is also involved in enhancing and expanding the technology platform.
Prior to Gatehouse Bio, Matt was a database engineer at Epic Hosting on the data analytics and administration team, where he developed automated systems and pipelines for SQL management and analytics workflows at multiple hospital systems.
Matt holds a PhD in chemical engineering from the University of Wisconsin-Madison; his dissertation work was on the development and application of methods for incorporating `omics data into genome-scale constraint-based metabolic models. He also holds an MS and BS in chemical engineering from the Pennsylvania State University.
Sarah is responsible for developing computational models to classify disease. She uses machine learning and statistical methods to find known and novel sRNA-signatures that are clinically relevant for diagnosis, subtyping, and drug target identification.
Sarah has held multiple roles as a data scientist in a diverse range of applications, including as an actuarial analyst at Cuna Mutual Group (Dublin, IE) and a data scientist at Vodafone Ireland.
Sarah holds an MSc in high performance computing from Trinity College Dublin (TCD) and a BSc (DCU) in actuarial mathematics from Dublin City University.